Diagnosis and treatment of refractory asthma

European Review for Medical and Pharmacological Sciences

Volumn 12, Issue 5, 2008, Pages 315-320

  Urso, D L ^a   Vincenzo, D ^a   Pignataro, F ^a   Acri, P ^a   Cucinotta, G ^a  

^a V Cosentino Hospital   (Italy)

Author keywords

2 agonists; Airflow obstruction; Corticosteroids; Refractory asthma

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; GLUCOCORTICOID; GOLD; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; METHOTREXATE; OMALIZUMAB; PREDNISOLONE; PREDNISONE; SALBUTAMOL; STEROID; THEOPHYLLINE;

AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EUROPE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MORNING DOSAGE; NORTH AMERICA; PEAK EXPIRATORY FLOW; PHYSICAL ACTIVITY; PNEUMONIA; PREVALENCE; RECURRENT DISEASE; SUSTAINED DRUG RELEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOCAL CORD DISORDER;

ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; HUMANS; RISK FACTORS;

EID: 56849109041     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. BURNEY PGJ. Epidemiology of asthma. Allergy 1993; 48: 17-21.
2. SERRA-BATLES J, PLAZA V, MOREJOU E, CORNELLA A, BRUGUES J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 1322-1326.
3. ANTONICELLI L, BUCCA C, NERI M, DE BENEDETTO F, SABBATANI P, BONIFAZI F, EICHLER HG, ZHANG Q, YNN DD. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23: 723-729.
4. PROCEEDING OF THE ATS WORKSHOP ON REFRACTORY ASTHMA. Am J Respir Crit Care Med 2000; 162: 2341-2351.
5. THE BTS/SIGN BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA APRIL 2004. Update Thorax 2003; Vol 58; Supplement I.
6. GLOBAL INITIATIVE FOR ASTHMA. Global strategy for asthma management and prevention. NIH Publication No 02-3659. Bethesda, National Institutes of Health/National Heart, Lung and Blood Institute, 2005.
7. AYRES JG, MILES JF, BARNES PJ. Brittle asthma. Thorax 1998; 53: 315-321
8. BARNES PJ, WOOLCOOK AJ. Difficult asthma. Eur Respir J 1998; 12: 1209-1218
9. ROBINSON DS, CAMPBELL DA, DURHAM SR, PFEFFER J, BARNES PJ, CHUNG KF; ASTHMA AND ALLERGY RESEARCH GROUP OF THE NATIONAL HEART AND LUNG INSTITUTE. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22: 478-483.
10. HEANEY LG, CONWAY E, KELLY C, JOHNSTON BT, ENGLISH C, STEVENSON M, GAMBLE J. Predictors of therapy resistant asthma: Outcome of a systematic evaluation protocol. Thorax 2003; 58: 561-566.
11. HEANEY LG, ROBINSON DS. Severe asthma treatment: Need for characterising patients. Lancet 2005; 365: 974-976.
12. BARREIRO E, GEA J, SANJUAS C, MARCOS R, BROOUETAS J, MILIC-EMILI J. Dyspnea at rest and at the end of different exercises in patients with near-fatal asthma. Eur Respir J 2004; 24: 219-225.
13. PELLEGRINO R, DECRAMER M, VAN SCHAYCK CP, DEKHUUZEN PN, TROOSTERS T, VAN HERWAARDEN C, OLIVIERI D, DEL DONNO M, DE BACKER W, LANKHORST I, ARDIA A. Quality control of spirometry: A lesson from the BRONCUS trial. Eur Respir J 2005; 26: 1104-1109.
14. STREK ME. Difficult asthma. Proc Am Thorac Soc 2006; 3: 116-123.
15. AMERICAN THORACIC SOCIETY. American Thoracic Society statement: guidelines for methacoline and exercise challenge testing-1999. Am J Respir Crit Care Med 2000; 161: 309-329.
16. CABANES LR, WEBER SN, MATRAN R, REGNARD J, RICHARD MO, DEGEORGES ME, LOCKHART A. Bronchial hyperesponsiveness to metacholine in patients with impaired left ventricular function. N Engl J Med 1989; 320: 1317-1322.
17. SZEFLER SJ, MARTIN RJ, KING TS, BOUSHEY HA, CHERNIACK RM, CHINCHILLI VM, CRAIG TJ, DOLOVICH M, DRAZEN JM, FAGAN JK, FAHY JV, FISH JE, FORD JG, ISRAEL E, KILEY J, KRAFT M, LAZARUS SC, LEMANSKE RF JR, MAUGER E, PETERS SP, SORKNESS CA, ASTHMA CLINICAL RESEARCH NETWORK OF THE NATIONAL HEART LUNG, AND BLOOD INSTITUTE. Significant variability in response to inhaled corticosteroids for persistent asthma. Ann Allergy Clin Immunol 2002; 109: 410-418.
18. BATEMAN ED, BOUSHEY HA, BOUSQUET J, BUSSE WW, CLARK TJ, PAUWELS RA, PEDERSEN SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.
19. EUROPEAN NETWORK FOR UNDERSTANDING MECHANISM OF SEVERE ASTHMA. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22: 470-477.
20. BARNES PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004; 1: 345-351.
21. SPAHN JD, LEUNG DYM, SURS W, HARBECK RJ, NIMMAGADDA S, SZEZLER SJ. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am J Respir Crit Care Med 1995; 151: 1709-1714.
22. MINOGUCHI K, KOHNO Y, MINOGUCHI H, KIHARA N, SANO Y, YASUARA H, ADACHI M. Reduction of eosinophilic inflammation in the airway of patient with asthma using montelukast. Chest 2002; 121: 732-738.
23. MARSHALL GD JR, SORKNESS CA. IgE-blocking therapy for difficult-to-treat asthma: A brief review. Manag Care 2004; 13: 45-50.
24. HILL SJ, TATTERSFIELD AE. Corticosteroid sparing agents in asthma. Thorax 1995; 50: 577-582